Frédéric Lemaître-Auger

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada.

Bio-MarCare Technologies Ltd. develops diagnostic kits based on novel biomarkers for early cancer identification, monitoring and assistance. Its product mCRC-Strat is a personalized medicine assay predicting responsiveness to anti EGFR therapy and Colon-MarCarePlex is a molecular assay (qRT-PCR) comprising a panel of RNA markers that can detect the advanced adenoma polyps as well as early stage colorectal cancer. The company was founded by Beatrice Uziely and Rachel Bar-Shavit in 2002 and is headquartered in Jerusalem, Israel.

Xagenic, Inc. develops the first lab-free molecular diagnostic platform. Its automated diagnostic platform will enable widespread decentralized testing to be performed outside of clinical laboratories. The firm's amplified redox assay detection technology utilizes electrochemical detection methods and does not rely on optical detection components or enzymatic amplification; crude samples can be analyzed with minimal sample processing. The company was founded by Shana O. Kelley and Edward Hartley Sargent in 2010 and is headquartered in Toronto, Canada.

Clinical Trials Ontario operates as a research and development company for various diseases. The company was founded in 2012 and is headquartered in Toronto, Canada.

Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

LifeBond Ltd. engages in the development of medical devices designed to restore and repair tissues to reduce post-operative complications. The company was founded by Nir Mashkif, Orahn Preiss-Bloom and Ishay Attar in 2007 and is headquartered in Caesarea, Israel.

Hadasit Bio-Holdings Ltd. /Private Equity/ (Hadasit Bio-Holdings /Private Equity/) is a private equity division of Hadasit Bio-Holdings Ltd. founded in 2005. The firm is headquartered in Jerusalem, Israel.

Hadasit Medical Research Services & Development Ltd. operates as technology transfer company of Hadassah Medical Center in Jerusalem. It identifies, protects, nurtures and commercializes the discoveries made at Hadassah Medical Center. The company's product include Doxil, Periochip, Travelan, Granagard, and Insupad. The company was founded on December 7, 1986 and is headquartered in Jerusalem, Israel.

Triphase Accelerator Corp. develops oncology drug therapeutics. It engages in accelerating oncology products from pre-investigational new drug (pre-IND) to Phase I/Phase II POC. The firm?s product includes Marizomib which is used in cancer treatment. The company is headquartered in Toronto, Canada.

Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel.

Vertex Pharmaceuticals (Canada), Inc. operates as a biotechnology company that invests in scientific innovation to create medicines for people with serious and life-threatening diseases. It discovered medicines to treat the cause of cystic fibrosis a genetic disease. The company is headquartered in Toronto, Canada.

CTI Life Sciences Fund provides life science related services. The private company is based in Montréal, Canada. The Canadian company was founded in 2006 by Kenneth Pastor.

Neurasic Therapeutics, Inc. develops opiate-sparing and pain-relieving drugs. The company was founded in June 2020 and is headquartered in Westmount, Canada.

The Institute of Corporate Directors is a not-for-profit, member-based association that serves as a resource and voice for directors and boards. The non-profit company is based in Toronto, Canada, and has subsidiaries in Canada. The ICD provides thought leadership through various publications and is a unified voice for directors. The Canadian company was founded by Brian J. Gibson, and Rahul K. Bhardwaj has been the CEO of the company since 2016.

The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California.

Precithera, Inc. engages in drug development business. The firm focuses on the design and the development of biological agents for the treatment of orphan diseases. The company was founded by Philippe Crine and Susan Schiavi on May 26, 2016 and is headquartered in Outremont, Canada.

Accel-Rx provides seed and start-up investment services to the new health sciences companies. It engages in leveraging investment support to the research and commercialization centers such as the existing health-related Centers of Excellence for Commercialization and Research (CECRs). The company was founded by Natalie Dakers in 2014 and is headquartered in Vancouver, Canada.

CTI Capital, Inc. is a Venture Capital firm, a subsidiary of CTI Capital Groupe, Inc. founded in 1987. CTI Capital, Inc. is headquartered in Montréal.